{"entity":{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","aka":[],"tldr":"Johns Hopkins is the birthplace of cancer genomics (Vogelstein), MSI-high immunotherapy (Le, Diaz), and liquid biopsy and MCED science (CancerSEEK).","summary":"Johns Hopkins Hospital and its Sidney Kimmel Comprehensive Cancer Center in Baltimore are where cancer genomics began with Vogelstein and Kinzler, and the centre holds NCI comprehensive designation and tenth place in the Newsweek/Statista oncology ranking. Its record includes pembrolizumab in mismatch-repair-deficient tumours, the first tumour-agnostic approval, led by Le and Diaz, the CancerSEEK liquid biopsy that fed Exact Sciences' multi-cancer early detection programme, and the Bloomberg-Kimmel Institute for Cancer Immunotherapy under Drew M. Pardoll and Elizabeth M. Jaffee. Nuclide links it to DELFI Diagnostics, to the DETECT-A, DYNAMIC and CheckMate 816 papers, and to pathways from epigenetic reprogramming to telomere maintenance. Whether blood-based early detection lowers harm as well as finding cancers is the question its own work posed. Programmes and people are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Baltimore","country":"US","lat":39.297,"lng":-76.593,"institutionType":"cancer-center","website":"https://www.hopkinsmedicine.org/kimmel-cancer-center","nci":"comprehensive","newsweekOncology2026":10,"university":"Johns Hopkins University","programs":["Cancer genomics","MSI-H immunotherapy","Liquid biopsy / MCED","Bloomberg-Kimmel Immunotherapy"]},"route":"/institutions/johns-hopkins/","neighbours":{"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"paper":[{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/"}]}}